Precision oncology has transformed who receives treatment and what biology we target. The next frontier is designing where therapeutic activity occurs.
- Crossing The Uncrossable: Skin Biology For The Delivery Of Peptide And Protein Therapeutics
- When The Adhesive Becomes The Drug Delivery System
- Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan
- Drug–Device Combination Products: Bridging Formulation, Device, And Manufacturing Decisions
- Rethinking Drug Delivery To Combat Antibiotic Resistance
- The Resurgence Of Fervor For Oral Delivery
- Advancing Multi-Pathology Disease-Modifying Therapy For Neurodegenerative Diseases
- Container Closure Systems For Biosimilars: Is There Regulatory Difference?
ON-DEMAND WEBINARS
See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.
Discover how revolutionary and environmentally sustainable nanoparticle technologies coupled with innovative formulation approaches can address drug solubility issues and add value for patients.
Explore the challenges related to packaging of cell and gene therapy products and proven solutions to enable speed to market and compatibility, performance of packaging materials.
Spray drying offers a solution to formulation challenges for enhancing the bioavailability of poorly soluble APIs but requires technical capability and operational excellence to accomplish the process successfully.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1448043410 3D printing]( "3D Screen Printing: Enabling A New Generation Of Complex Formulations")
3D Screen Printing: Enabling A New Generation Of Complex FormulationsScreen-Printed Innovative Drug Technology can produce oral, transdermal, and implantable dosage forms while ensuring heterogeneous distribution of active ingredients.
-
![West]( "Viral Vector Based Gene Therapy Drug Products: The Right Primary Container")
Viral Vector Based Gene Therapy Drug Products: The Right Primary ContainerExplore the major considerations for an ideal primary container for viral vector-based gene therapy drug products and the existing and new solutions in this space.
-
![GettyImages-1310024666-genetic-digital-dna]( "How Nanoparticle Platforms Are Unlocking Genetic Medicine's Potential")
How Nanoparticle Platforms Are Unlocking Genetic Medicine's PotentialExplore how the HIT SCAN platform accelerates gene therapy delivery by screening polymeric nanoparticles, enhancing precision and regulatory pathways for next-generation genetic medicines.
-
![Oct2020bucket]( "Leveraging Integration At Each Phase Of A Drug Delivery System Project")
Leveraging Integration At Each Phase Of A Drug Delivery System ProjectBy forging deeper partnerships with customers, the full depth and breadth of our knowledge, experience and competencies can bring benefits at multiple levels. See how an integrated offering helps at each phase of a drug delivery system project.
-
![West]( "Vial Containment Systems For Gene And Cell Therapies")
Vial Containment Systems For Gene And Cell TherapiesCZ vial-stopper-seal combinations offer a viable solution for the challenges associated with low-temperature storage of cell therapy drug products.
-
![Vials GettyImages-1316775813]( "Four Special Fill/Finish Considerations For Vaccine Production")
Four Special Fill/Finish Considerations For Vaccine ProductionExamine considerations regarding the handling and process for fill/finish to ensure the stability and purity of your vaccine as well as limit unnecessary waste and cost.
-
![BD2]( "Leveraging Autoinjector Innovation To De-Risk Biosimilar Development")
Leveraging Autoinjector Innovation To De-Risk Biosimilar DevelopmentDiscover how a biopharmaceutical company can de-risk the launch process by choosing a suitable autoinjector technology and partner.
-
![med-device-implants-GettyImages-1288230443]( "Beyond The Battery: Powering the Next Generation Of Active Implants")
Beyond The Battery: Powering the Next Generation Of Active ImplantsActive implants are pushing past battery limits as energy‑harvesting taps motion, heat, and biochemical signals. Hybrid systems could shrink devices and enable longer‑lasting, self‑powered implants.
-
![GettyImages-1435491000-manufacturing-tablet-robot-production]( "Closing The Care Gap: Clinician Assistive Technologies")
Closing The Care Gap: Clinician Assistive TechnologiesThis technology addresses workforce shortages and growing medical complexity by helping healthcare providers manage rising demands, improve efficiency, reduce errors, and extend care access.
-
![Dual_chamber_picture_1 (1)]( "De-Risking A Novel Valve Component For Use With Standard Syringe Systems")
De-Risking A Novel Valve Component For Use With Standard Syringe SystemsA novel valve provides dual‑chamber functionality within standard syringes, keeping two liquid drugs separated until injection while reducing development risk through advanced modeling.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.
DELIVERED BY DEGRAZIO
-
![Delivered _by _DeGrazio_Logo_Color_2]( "Container Closure Systems For Biosimilars: Is There Regulatory Difference?")
Container Closure Systems For Biosimilars: Is There Regulatory Difference?In this article, Fran DeGrazio discusses the FDA’s draft guidance on container closure systems for biosimilar products. She highlights key takeaways and offers recommendations on implications that developers of biosimilar pharmaceutical products should consider in areas such as quality, testing, and documentation.
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts.
